Dr Sulaiman Al-Habib Medical Services Group Co
SAU:4013
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
272.6
335.4341
|
Price Target |
|
We'll email you a reminder when the closing price reaches SAR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Dr Sulaiman Al-Habib Medical Services Group Co
EPS (Diluted)
Dr Sulaiman Al-Habib Medical Services Group Co
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Dr Sulaiman Al-Habib Medical Services Group Co
SAU:4013
|
EPS (Diluted)
ď·Ľ5
|
CAGR 3-Years
25%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
||
Dallah Healthcare Company SJSC
SAU:4004
|
EPS (Diluted)
ď·Ľ4
|
CAGR 3-Years
22%
|
CAGR 5-Years
30%
|
CAGR 10-Years
12%
|
||
National Medical Care Company JSC
SAU:4005
|
EPS (Diluted)
ď·Ľ6
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
10%
|
||
Mouwasat Medical Services Company SJSC
SAU:4002
|
EPS (Diluted)
ď·Ľ3
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
3%
|
||
A
|
Al Hammadi Holding Co
SAU:4007
|
EPS (Diluted)
ď·Ľ2
|
CAGR 3-Years
19%
|
CAGR 5-Years
24%
|
CAGR 10-Years
4%
|
|
D
|
Dr Soliman Abdel Kader Fakeeh Hospital Company SCJSC
SAU:4017
|
EPS (Diluted)
ď·Ľ1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Dr Sulaiman Al-Habib Medical Services Group Co
Glance View
Dr. Sulaiman Al-Habib Medical Services Group Co., often recognized as a titan in the healthcare landscape of the Middle East, has woven a narrative marked by strategic expansion and unwavering commitment to quality patient care since its inception. Founded by the visionary Dr. Sulaiman Al-Habib, the company has grown to encapsulate a network of modern, state-of-the-art hospitals, medical centers, and pharmacies across Saudi Arabia, the United Arab Emirates, and Bahrain. This healthcare conglomerate is renowned for merging cutting-edge technology with experienced medical professionals to deliver comprehensive healthcare services, ranging from preventative care to complex surgical procedures. They have successfully carved a niche by emphasizing an integrated approach to treatment, thus creating a robust model that emphasizes patient safety and satisfaction as the core pillars of its operations. Revenue generation for Dr. Sulaiman Al-Habib Medical Services Group is intricately linked to its broad spectrum of services, which includes outpatient care, inpatient treatment, laboratory services, imaging facilities, and pharmaceutical sales. Their diversified service model allows them to serve a wide demographic, catering to the rising demand for specialized medical services in the region. Beyond the conventional healthcare setup, the group also thrives on its foray into digital healthcare solutions, which include telemedicine services and electronic health records, reflecting a keen adaptability to contemporary technological advancements. This adaptive strategy not only enhances operational efficiency but also strengthens patient engagement, thereby ensuring a steady stream of revenue while simultaneously fostering trust and loyalty among its patients. In essence, Dr. Sulaiman Al-Habib Medical Services Group exemplifies a balanced paradigm of healthcare excellence and business acumen, contributing significantly to the elevation of healthcare standards in the Middle East.
See Also
What is Dr Sulaiman Al-Habib Medical Services Group Co's EPS (Diluted)?
EPS (Diluted)
5.9
SAR
Based on the financial report for Dec 31, 2023, Dr Sulaiman Al-Habib Medical Services Group Co's EPS (Diluted) amounts to 5.9 SAR.
What is Dr Sulaiman Al-Habib Medical Services Group Co's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
21%
Over the last year, the EPS (Diluted) growth was 24%. The average annual EPS (Diluted) growth rates for Dr Sulaiman Al-Habib Medical Services Group Co have been 25% over the past three years , 21% over the past five years .